Bo Yan

5.6k total citations · 1 hit paper
193 papers, 4.3k citations indexed

About

Bo Yan is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Bo Yan has authored 193 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Molecular Biology, 36 papers in Oncology and 36 papers in Epidemiology. Recurrent topics in Bo Yan's work include Autophagy in Disease and Therapy (22 papers), Lung Cancer Treatments and Mutations (16 papers) and MicroRNA in disease regulation (15 papers). Bo Yan is often cited by papers focused on Autophagy in Disease and Therapy (22 papers), Lung Cancer Treatments and Mutations (16 papers) and MicroRNA in disease regulation (15 papers). Bo Yan collaborates with scholars based in China, United States and Germany. Bo Yan's co-authors include Shuchao Pang, Xiaodong Wang, Sally A. Moody, Youwei Ai, Angang Yang, Yan Ma, Zhiyuan Zhang, Yang Cao, Jiawen Wang and Qi Sun and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Bo Yan

186 papers receiving 4.2k citations

Hit Papers

Membrane Damage during Ferroptosis Is Caused by Oxidation... 2020 2026 2022 2024 2020 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bo Yan China 35 2.2k 1.1k 791 616 575 193 4.3k
Xianghui Fu China 36 2.4k 1.1× 1.3k 1.2× 474 0.6× 710 1.2× 502 0.9× 103 4.1k
Anna Asplund Sweden 32 3.7k 1.7× 983 0.9× 475 0.6× 723 1.2× 500 0.9× 71 5.3k
Tong Liu China 34 2.2k 1.0× 1.3k 1.2× 853 1.1× 652 1.1× 362 0.6× 142 3.8k
Yue Zhang China 39 3.1k 1.4× 1.7k 1.6× 518 0.7× 628 1.0× 432 0.8× 200 5.0k
Yangfu Jiang China 31 2.7k 1.2× 1.2k 1.2× 456 0.6× 1.1k 1.8× 415 0.7× 70 4.9k
Yun‐Yong Park South Korea 34 2.2k 1.0× 827 0.8× 388 0.5× 844 1.4× 258 0.4× 71 3.5k
Guoping Cai United States 31 2.9k 1.3× 1.7k 1.6× 477 0.6× 652 1.1× 314 0.5× 203 4.9k
Marc Legeay France 3 3.3k 1.5× 876 0.8× 799 1.0× 453 0.7× 344 0.6× 6 5.3k
Alexander T.H. Wu Taiwan 40 2.6k 1.2× 1.1k 1.0× 684 0.9× 1.1k 1.8× 292 0.5× 170 5.1k
Kwang‐Hee Bae South Korea 35 3.0k 1.3× 891 0.8× 512 0.6× 451 0.7× 654 1.1× 152 4.6k

Countries citing papers authored by Bo Yan

Since Specialization
Citations

This map shows the geographic impact of Bo Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Yan more than expected).

Fields of papers citing papers by Bo Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Yan. The network helps show where Bo Yan may publish in the future.

Co-authorship network of co-authors of Bo Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Yan. A scholar is included among the top collaborators of Bo Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Yan. Bo Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merle, Nicolas S., Martin Kolev, Erin E. West, et al.. (2025). Peptide-mediated modulation of complement-like CD109 boosts T cell anti-tumor responses 2967. The Journal of Immunology. 214(Supplement_1).
4.
Yan, Bo, Tianqing Chu, Hua Zhong, et al.. (2024). 649P An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome. Annals of Oncology. 35. S1647–S1647. 1 indexed citations
5.
Jin, Juan, et al.. (2023). Factors Associated with Intestinal Polyp Recurrence after Electroresection. Journal of College of Physicians And Surgeons Pakistan. 33(6). 633–637. 2 indexed citations
6.
Yan, Bo, Wenbin Zhang, Gaihong Cai, et al.. (2022). Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death. Cell chemical biology. 29(6). 958–969.e5. 18 indexed citations
7.
Guo, Jia, Zehui Guo, Bo Yan, et al.. (2022). Blockage of MLKL prevents myelin damage in experimental diabetic neuropathy. Proceedings of the National Academy of Sciences. 119(14). e2121552119–e2121552119. 11 indexed citations
8.
Wang, Yong, et al.. (2021). The Clinical Significance and Functional Role of miR-466 in Gastric Cancer Peritoneal Metastasis. Molecular Biotechnology. 64(1). 25–32. 3 indexed citations
9.
Han, Baohui, Bo Yan, Aiqin Gu, et al.. (2021). 1238P AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients. Annals of Oncology. 32. S977–S977. 2 indexed citations
10.
Chen, Yulong, Lianmin Zhang, Bo Yan, et al.. (2020). Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. Translational Lung Cancer Research. 9(3). 761–767. 10 indexed citations
11.
Yan, Bo, et al.. (2019). Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers. Clinical Genetics. 97(1). 64–72. 25 indexed citations
12.
Zhang, Xiang, Xiao Zhang, Ting Wang, et al.. (2018). MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma. Cancer Letters. 426. 98–108. 47 indexed citations
13.
Cai, Yanhui, et al.. (2016). Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells. Cancer Letters. 381(1). 104–112. 14 indexed citations
14.
Ouyang, Qing, et al.. (2015). [Application of molecular chaperones to soluble expression of e23sFv/His fusion proteins].. PubMed. 31(9). 1205–10. 1 indexed citations
15.
Yan, Bo, et al.. (2013). Short Communication Development of universal primers for isolating fragments of the LEAFY gene. Genetics and Molecular Research. 12(2). 1777–1780. 1 indexed citations
16.
Zhang, Aimei, et al.. (2012). Genetic analysis of SIRT1 gene promoter in sporadic Parkinson’s disease. Biochemical and Biophysical Research Communications. 422(4). 693–696. 41 indexed citations
17.
Yan, Bo, Jie Ge, Bin Zhang, & Xuchen Cao. (2011). Application of a carbon nanoparticle suspension injection into the mammary gland in the sentinel lymph node biopsy for breast cancer. Clinical Oncology and Cancer Research. 38(21). 1335–1337. 1 indexed citations
18.
Wu, Guanghua, et al.. (2011). Decreased gene expression of LC3 in peripheral leucocytes of patients with coronary artery disease. European Journal of Clinical Investigation. 41(9). 958–963. 17 indexed citations
19.
Neilson, Karen M., Francesca Pignoni, Bo Yan, & Sally A. Moody. (2010). Developmental expression patterns of candidate cofactors for vertebrate six family transcription factors. Developmental Dynamics. 239(12). 3446–3466. 25 indexed citations
20.
Yan, Bo, et al.. (1993). A new hypothesis about the relationship between free radical reactions and hemorheological properties in vivo. Medical Hypotheses. 41(6). 516–520. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026